| abstract |
The invention relates to a universal tumour-associated oligopeptide, which is recognised by CD8-positive cytotoxic T-lymphocytes (CTL) as a peptide antigen and which causes a CTL-induced lysis and/or apoptosis of tumour or leukaemia cells. The oligopeptide has the amino acid sequence LLGDLFGV, which corresponds to the amino acid positions 81 to 88 of the hdm2 proto-oncoprotein, or an amino acid sequence that can be derived from said sequence, which constitutes the functional equivalent of the amino acid sequence LLGDLFGV. Said oligopeptide constitutes an epitope for CD8-positive CTLs and is suitable for inducing a restricted immune response of CD8-positive CTLs to the human leukocyte antigen of the molecular group MHC class I, allelomorph variant A2, against tumour and leukaemia cells. |